Lenvatinib Mesylate CAS 857890-39-2 Assay 98.0~102.0% Factory

Lenvatinib Mesylate (CAS: 857890-39-2) ndi oral and multitargeted inhibitor ya VEGFR1-3, FGFR1-4, PDGFR, KIT, ndi RET, yokhala ndi ntchito zamphamvu zotsutsana ndi zotupa.Lenvatinib Mesylate ndi receptor tyrosine kinase (RTK) inhibitor yomwe ili ndi kusankha kwa VEGFR2.Imawonetsa ntchito ya antineoplastic, ndipo yasonyezedwa pofuna kuchiza odwala omwe ali ndi khansa ya chithokomiro yodziwika bwino kapena ya metastatic, yopita patsogolo, ya radioactive (RAI) -refractory.Lenvatinib Mesylate idavomerezedwa koyamba ndi US Food and Drug Administration (FDA) pa Feb 13, 2015, kenako idavomerezedwa ndi Pharmaceuticals and Medical Devices Agency of Japan (PMDA) pa Mar 26, 2015, ndikuvomerezedwa ndi European Medicine Agency (EMA) pa May 28, 2015. Idapangidwa ndikugulitsidwa ngati Lenvima® ndi Eisai.Lenvatinib Mesylate ndi oral multiple receptor tyrosine kinase inhibitor yokhala ndi njira yapadera yomangiriza yomwe imalepheretsa mwapadera zochitika za vascular endothelial growth factor (VEGF) zolandilira, kuphatikiza pa proangiogenic ndi oncogenic pathway-zokhudzana ndi tyrosine kinases zomwe zimaganiziridwa kuti zimakhudzidwa ndi kuchuluka kwa chotupa. .Iwo anasonyeza zochizira patsogolo radioiodine-refractory kusiyana chithokomiro khansa.Lenvimaimagwiritsidwa ntchito yokha pochiza differentiated thyroid cancer (DTC), mtundu wa khansa ya chithokomiro yomwe sichithanso kuchiritsidwa ndi ayodini wa radioactive ndipo ikupita patsogolo.LENVIMA imagwiritsidwa ntchito limodzi ndi mankhwala ena otchedwa everolimus pochiza akuluakulu omwe ali ndi mtundu wa khansa ya impso yotchedwa advanced renal cell carcinoma (RCC) pambuyo pa chithandizo chimodzi ndi mankhwala ena oletsa khansa.